Group 1 - The annual performance ranking of public funds is approaching, with the leading fund maintaining its top position but with a narrowing advantage [1][2] - As of November 16, the average return for equity funds is 28.72%, mixed funds at 25.53%, QDII at 24.28%, FOF at nearly 15%, bond funds over 2%, and money market funds over 1% [1] - Over 12,600 out of 13,300 public fund products have positive returns this year, representing a high proportion of 95% [1] Group 2 - The top-performing fund, Yongying Technology Smart Selection Mixed Fund A, has a cumulative net value increase of 184.04%, leading the second place by less than 38 percentage points [2] - The second place is held by Hengyue Advantage Selected Mixed Fund with a net value increase of 146.88%, followed by GF Growth Navigation One-Year Holding Mixed Fund at 140.6% [2] - The performance gap between the second to fourth ranked funds is small, with several funds showing net value increases between 118% and 122%, indicating potential changes before year-end [2]

Core Viewpoint - The article highlights that pharmaceutical-themed funds have emerged as the top performers in the public fund market for the first half of 2025, with a significant focus on Hong Kong stocks and a concentrated investment strategy in specific sectors like oncology and metabolic diseases [2][5][7]. Group 1: Performance Rankings - In the first half of 2025, seven out of the top ten performing public funds were pharmaceutical-themed, with the top fund, Huatai-PB Hong Kong Advantage Selected Fund, achieving a return of 86% [3][5]. - Other notable funds in the top ten include CITIC Securities North Exchange Selected Fund and Great Wall Pharmaceutical Industry Selected Fund, with returns of 82.45% and 75.18% respectively [3][5]. - The top ten funds all had returns exceeding 61%, indicating a strong performance across the board [3]. Group 2: Investment Strategies - Nine out of the top ten funds employed a single-sector investment strategy, demonstrating the effectiveness of this approach in achieving high performance [4]. - The only fund that adopted a balanced strategy, the Great Wall Growth Leading Fund, still managed to achieve a return of 68.29% despite its diversified holdings [4]. Group 3: Importance of Hong Kong Stocks - The allocation to Hong Kong stocks, particularly in the innovative pharmaceutical sector, has been crucial for the performance of these funds [5][6]. - The top-performing funds have significantly increased their exposure to Hong Kong pharmaceutical stocks, with the Huatai-PB fund allocating 86% of its holdings to this sector [5][6]. - The trend indicates a blurring of lines between A-share and Hong Kong fund definitions as A-share funds increasingly allocate to Hong Kong stocks due to better valuation and growth prospects [5][6]. Group 4: Market Dynamics and Future Outlook - The innovative pharmaceutical sector is expected to continue leading market performance, driven by policy support, capital influx, and industry momentum [7][9]. - The article notes that the differences between Hong Kong and A-share markets are narrowing, with both markets benefiting from similar valuation dynamics and capital flows [8]. - The long-term outlook for companies with strong R&D capabilities and significant product potential remains positive, despite short-term volatility [9].

Core Insights - Public funds' performance rankings for the first half of the year are about to be released, with pharmaceutical funds standing out due to significant excess returns [1] - As of June 18, pharmaceutical funds achieved an average net value growth rate exceeding 19%, capturing nearly half of the top 100 fund performance rankings for the year [1] - This has sparked widespread market interest in the pharmaceutical sector, particularly in the innovative drug field [1]